Rockville, Md., USA - April 8, 2013, Rockville, Md., USA - EntreMed, Inc., a clinical-stage pharmaceutical company, announced that it has named James Huang and Y. Alexander Wu as directors.
Article continues below
Mr. Huang is Managing Partner of Kleiner Perkins Caufield Byers China and General Partner of KPCB China Fund II, LP. Prior to Kleiner Perkins, Mr. Huang was Managing Partner at Vivo Ventures LLC, a venture capital firm specializing in life science investments. Mr. Huang has more than 20 years of experience in the pharmaceutical and biopharmaceutical industry.
During this time, he has held senior roles in business development, sales, marketing and R&D with Anesiva, Inc., Tularik Inc., GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. Mr. Huang received a B.S. degree in chemical engineering from the University of California, Berkley and a M.B.A. from the Stanford Graduate School of Business.
Dr. Wu is co-founder and CEO of Crown Bioscience, Inc., a drug discovery and preclinical research organization. Before co-founding Crown Bioscience, Dr. Wu was Chief Business Officer of Starvax International Inc., a biopharmaceutical R&D company. Prior to Starvax, he was the Head of Asian Operations with Burrill & Company, a life science venture capital and merchant bank.
Dr. Wu also co-founded and was Chief Operating Officer of Unimicro Technologies, a life science instrumentation company. He started his career with Hoffmann-La Roche, where he was Manager of Business Development and Strategic Planning. Dr. Wu obtained his B.S. in biochemistry from Fudan University, China, a M.S. in Biochemistry from the University of Illinois, and a Ph.D. in molecular cell biology and MBA from the University of California, Berkeley.
EntreMed also announced that Mark C. M. Randall has resigned from its Board of Directors.
EntreMed further announced that Ken K. Ren, Ph.D. has been appointed Chief Executive Officer, after having completed his one-year term as interim CEO.
Prior to joining EntreMed from 2005-2012, Dr. Ren was the president of Accelovance (China), a subsidiary of Accelovance, Inc. Prior to Accelovance, Dr. Ren was the founder of New Jersey-based AHT Inc., which merged with Novemed, a portfolio investment of a blue-chip public company in Hong Kong.
He was a co-founder of the China Innovation Center for Life Science (U.S.A.) Corp., a New York-based consulting firm in partnership with the Chinese Ministry of Science and Technology which provided consulting services to health-care and pharmaceutical companies in both the U.S. and China. Over the past 15 years Dr. Ren has been involved in several U.S./China based start-up companies in pharmaceutical development or services. ■